Clostridium difficile - From colonization to infection

Frontiers in Microbiology

Volumn 9, Issue APR, 2018, Pages

  Schäffler, Holger ^a   Breitrück, Anne ^a,b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

Asymptomatic colonization; CDI; Clostridium difficile; Clostridium difficile infection; Microbiota

Indexed keywords

ACTOXUMAB; ANTIBIOTIC AGENT; BACTERIOCIN; BEZLOTOXUMAB; BILE ACID; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL FLORA; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE PREDISPOSITION; FECAL MICROBIOTA TRANSPLANTATION; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PREVALENCE; PSEUDOMEMBRANOUS COLITIS; REVIEW;

EID: 85045283196     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2018.00646     Document Type: Review

References (208)

1. Akhtar, A. J., and Shaheen, M. (2007). Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J. Natl. Med. Assoc. 99, 500-504
2. al Saif, N., and Brazier, J. S. (1996). The distribution of Clostridium difficile in the environment of South Wales. J. Med. Microbiol. 45, 133-137. doi: 10.1099/00222615-45-2-133
3. Alasmari, F., Seiler, S. M., Hink, T., Burnham, C.-A. D., and Dubberke, E. R. (2014). Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin. Infect. Dis. 59, 216-222. doi: 10.1093/cid/ciu258
4. Ananthakrishnan, A. N. (2011). Clostridium difficile infection: epidemiology, risk factors and management. Nat. Rev. Gastroenterol. Hepatol. 8, 17-26. doi: 10.1038/nrgastro.2010.190
5. Antharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., et al. (2013). Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51, 2884-2892. doi: 10.1128/JCM.00845-13
6. Antonopoulos, D. A., Huse, S. M., Morrison, H. G., Schmidt, T. M., Sogin, M. L., and Young, V. B. (2009). Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect. Immun. 77, 2367-2375. doi: 10.1128/IAI.01520-08
7. Antunes, L. C. M., and Finlay, B. B. (2011). A comparative analysis of the effect of antibiotic treatment and enteric infection on intestinal homeostasis. Gut Microbes 2, 105-108. doi: 10.4161/gmic.2.2.15610
8. Arbel, L. T., Hsu, E., and McNally, K. (2017). Cost-effectiveness of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection: a literature review. Cureus 9:e1599. doi: 10.7759/cureus.1599
9. Aronsson, B., Möllby, R., and Nord, C. E. (1985). Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J. Infect. Dis. 151, 476-481. doi: 10.1093/infdis/151.3.476
10. Arvand, M., Moser, V., Schwehn, C., Bettge-Weller, G., Hensgens, M. P., and Kuijper, E. J. (2012). High prevalence of Clostridium difficile colonization among nursing home residents in Hesse, Germany. PLoS One 7:e30183. doi: 10.1371/journal.pone.0030183
11. Bacci, S., Mølbak, K., Kjeldsen, M. K., and Olsen, K. E. P. (2011). Binary toxin and death after Clostridium difficile infection. Emerg. Infect. Dis. 17, 976-982. doi: 10.3201/eid/1706.101483
12. Bacon, A. E., Fekety, R., Schaberg, D. R., and Faix, R. G. (1988). Epidemiology of Clostridium difficile colonization in newborns: results using a bacteriophage and bacteriocin typing system. J. Infect. Dis. 158, 349-354. doi: 10.1093/infdis/158.2.349
13. Bagdasarian, N., Rao, K., and Malani, P. N. (2015). Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313, 398-408. doi: 10.1001/jama.2014.17103
14. Bakri, M. M., Brown, D. J., Butcher, J. P., and Sutherland, A. D. (2009). Clostridium difficile in ready-to-eat salads, Scotland. Emerg. Infect. Dis. 15, 817-818. doi: 10.3201/eid1505.081186
15. Barbut, F., Cornely, O. A., Fitzpatrick, F., Kuijper, E. J., Nagy, E., Rupnik, M., et al. (2013). Clostridium difficile Infection in Europe: A CDI Europe Report. Available at: http://www.multivu.com/assets/60637/documents/60637-CDI-HCP-Report-original.pdf [accessed March 05, 2018]
16. Bartlett, J. G. (2006). Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145, 758-764. doi: 10.7326/0003-4819-145-10-200611210-00008
17. Bartlett, J. G. (2010). Clostridium difficile: progress and challenges. Ann. N. Y. Acad. Sci. 1213, 62-69. doi: 10.1111/j.1749-6632.2010.05863.x
18. Bartlett, J. G., Chang, T. W., and Onderdonk, A. B. (1978). Comparison of five regimens for treatment of experimental clindamycin-associated colitis. J. Infect. Dis. 138, 81-86. doi: 10.1093/infdis/138.1.81
19. Bartlett, J. G., Onderdonk, A. B., Cisneros, R. L., and Kasper, D. L. (1977). Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J. Infect. Dis. 136, 701-705. doi: 10.1093/infdis/136.5.701
20. Bartoloni, A., Mantella, A., Goldstein, B. P., Dei, R., Benedetti, M., Sbaragli, S., et al. (2004). In-vitro activity of nisin against clinical isolates of Clostridium difficile. J. Chemother. 16, 119-121. doi: 10.1179/joc.2004.16.2.119
21. Bauer, M. P., Farid, A., Bakker, M., Hoek, R. A. S., Kuijper, E. J., and van Dissel, J. T. (2014). Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile. Clin. Microbiol. Infect. 20, O446-O449. doi: 10.1111/1469-0691.12439
22. Bauer, M. P., Notermans, D. W., van Benthem, B. H. B., Brazier, J. S., Wilcox, M. H., Rupnik, M., et al. (2011). Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377, 63-73. doi: 10.1016/S0140-6736(10)61266-4
23. Bavishi, C., and Dupont, H. L. (2011). Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther. 34, 1269-1281. doi: 10.1111/j.1365-2036.2011.04874.x
24. Begley, M., Hill, C., and Gahan, C. G. M. (2006). Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72, 1729-1738. doi: 10.1128/AEM.72.3.1729-1738.2006
25. Blaser, M. J. (2014). The microbiome revolution. J. Clin. Invest. 124, 4162-4165. doi: 10.1172/JCI78366
26. Bolton, R. P., Tait, S. K., Dear, P. R., and Losowsky, M. S. (1984). Asymptomatic neonatal colonisation by Clostridium difficile. Arch. Dis. Child. 59, 466-472. doi: 10.1136/adc.59.5.466
27. Borriello, S. P., Honour, P., Turner, T., and Barclay, F. (1983). Household pets as a potential reservoir for Clostridium difficile infection. J. Clin. Pathol. 36, 84-87. doi: 10.1136/jcp.36.1.84
28. Brouwer, M. S. M., Roberts, A. P., Hussain, H., Williams, R. J., Allan, E., and Mullany, P. (2013). Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat. Commun. 4:2601. doi: 10.1038/ncomms3601
29. Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., et al. (2015). Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205-208. doi: 10.1038/nature13828
30. Buffie, C. G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., et al. (2012). Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80, 62-73. doi: 10.1128/IAI.05496-11
31. Buonomo, E. L., and Petri, W. A. (2016). The microbiota and immune response during Clostridium difficile infection. Anaerobe 41, 79-84. doi: 10.1016/j.anaerobe.2016.05.009
32. Campbell, R. R., Beere, D., Wilcock, G. K., and Brown, E. M. (1988). Clostridium difficile in acute and long-stay elderly patients. Age Ageing 17, 333-336. doi: 10.1093/ageing/17.5.333
33. Carroll, K. C., and Bartlett, J. G. (2011). Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu. Rev. Microbiol. 65, 501-521. doi: 10.1146/annurev-micro-090110-102824
34. Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., et al. (2008). Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435-438. doi: 10.1086/525047
35. Chang, V. T., and Nelson, K. (2000). The role of physical proximity in nosocomial diarrhea. Clin. Infect. Dis. 31, 717-722. doi: 10.1086/314030
36. Chen, X., Katchar, K., Goldsmith, J. D., Nanthakumar, N., Cheknis, A., Gerding, D. N., et al. (2008). A mouse model of Clostridium difficile-associated disease. Gastroenterology 135, 1984-1992. doi: 10.1053/j.gastro.2008.09.002
37. Cheng, S. H., Lu, J. J., Young, T. G., Perng, C. L., and Chi, W. M. (1997). Clostridium difficile-associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results. Clin. Infect. Dis. 25, 157-158. doi: 10.1086/516891
38. Clooten, J., Kruth, S., Arroyo, L., and Weese, J. S. (2008). Prevalence and risk factors for Clostridium difficile colonization in dogs and cats hospitalized in an intensive care unit. Vet. Microbiol. 129, 209-214. doi: 10.1016/j.vetmic.2007.11.013
39. Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., et al. (2010). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455. doi: 10.1086/651706
40. Cornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., et al. (2012). Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12, 281-289. doi: 10.1016/S1473-3099(11)70374-7
41. Cotter, P. D., Hill, C., and Ross, R. P. (2005). Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3, 777-788. doi: 10.1038/nrmicro1273
42. Cowardin, C. A., and Petri, W. A. (2014). Host recognition of Clostridium difficile and the innate immune response. Anaerobe 30, 205-209. doi: 10.1016/j.anaerobe.2014.08.014
43. Curry, S. R., Marsh, J. W., Muto, C. A., O'Leary, M. M., Pasculle, A. W., and Harrison, L. H. (2007). tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J. Clin. Microbiol. 45, 215-221. doi: 10.1128/JCM.01599-06
44. Curry, S. R., Muto, C. A., Schlackman, J. L., Pasculle, A. W., Shutt, K. A., Marsh, J. W., et al. (2013). Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin. Infect. Dis. 57, 1094-1102. doi: 10.1093/cid/cit475
45. De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., et al. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U.S.A. 107, 14691-14696. doi: 10.1073/pnas.1005963107
46. Debast, S. B., Bauer, M. P., and Kuijper, E. J. (2014). European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 20(Suppl. 2), 1-26. doi: 10.1111/1469-0691.12418
47. Deshpande, A., Pant, C., Pasupuleti, V., Rolston, D. D. K., Jain, A., Deshpande, N., et al. (2012). Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin. Gastroenterol. Hepatol. 10, 225-233. doi: 10.1016/j.cgh.2011.09.030
48. Dethlefsen, L., Huse, S., Sogin, M. L., and Relman, D. A. (2008). The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6:e280. doi: 10.1371/journal.pbio.0060280
49. Dethlefsen, L., and Relman, D. A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1), 4554-4561. doi: 10.1073/pnas.1000087107
50. Dial, S., Alrasadi, K., Manoukian, C., Huang, A., and Menzies, D. (2004). Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171, 33-38. doi: 10.1503/cmaj.1040876
51. Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., et al. (2010). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U.S.A. 107, 11971-11975. doi: 10.1073/pnas.1002601107
52. Drudy, D., Fanning, S., and Kyne, L. (2007). Toxin A-negative, toxin B-positive Clostridium difficile. Int. J. Infect. Dis. 11, 5-10. doi: 10.1016/j.ijid.2006.04.003
53. Dubberke, E. R., and Olsen, M. A. (2012). Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55(Suppl. 2), S88-S92. doi: 10.1093/cid/cis335
54. Dupuy, B., Govind, R., Antunes, A., and Matamouros, S. (2008). Clostridium difficile toxin synthesis is negatively regulated by TcdC. J. Med. Microbiol. 57, 685-689. doi: 10.1099/jmm.0.47775-0
55. Eglow, R., Pothoulakis, C., Itzkowitz, S., Israel, E. J., O'Keane, C. J., Gong, D., et al. (1992). Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J. Clin. Invest. 90, 822-829. doi: 10.1172/JCI115957
56. Eyre, D. W., Griffiths, D., Vaughan, A., Golubchik, T., Acharya, M., O'Connor, L., et al. (2013). Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One 8:e78445. doi: 10.1371/journal.pone.0078445
57. Fekety, R., and Shah, A. B. (1993). Diagnosis and treatment of Clostridium difficile colitis. JAMA 269, 71-75. doi: 10.1001/jama.1993.03500010081036
58. Furuya-Kanamori, L., Marquess, J., Yakob, L., Riley, T. V., Paterson, D. L., Foster, N. F., et al. (2015). Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infect. Dis. 15:516. doi: 10.1186/s12879-015-1258-4
59. Gao, L., Maidment, I., Matthews, F. E., Robinson, L., and Brayne, C. (2018). Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II. Age Ageing 47, 220-225. doi: 10.1093/ageing/afx158
60. Garibaldi, R. A., and Nurse, B. A. (1986). Infections in the elderly. Am. J. Med. 81, 53-58. doi: 10.1016/0002-9343(86)90514-0
61. Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., and Silva, J. (1995). Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16, 459-477. doi: 10.2307/30141083
62. Gerding, D. N., Johnson, S., Rupnik, M., and Aktories, K. (2014). Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5, 15-27. doi: 10.4161/gmic.26854
63. Gerding, D. N., Meyer, T., Lee, C., Cohen, S. H., Murthy, U. K., Poirier, A., et al. (2015). Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719-1727. doi: 10.1001/jama.2015.3725
64. Gerding, D. N., Muto, C. A., and Owens, R. C. (2008). Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1), S43-S49. doi: 10.1086/521861
65. Geric, B., Carman, R. J., Rupnik, M., Genheimer, C. W., Sambol, S. P., Lyerly, D. M., et al. (2006). Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 193, 1143-1150. doi: 10.1086/501368
66. Giel, J. L., Sorg, J. A., Sonenshein, A. L., and Zhu, J. (2010). Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 5:e8740. doi: 10.1371/journal.pone.0008740
67. Gil, F., Lagos-Moraga, S., Calderón-Romero, P., Pizarro-Guajardo, M., and Paredes-Sabja, D. (2017). Updates on Clostridium difficile spore biology. Anaerobe 45, 3-9. doi: 10.1016/j.anaerobe.2017.02.018
68. Guerrero, D. M., Becker, J. C., Eckstein, E. C., Kundrapu, S., Deshpande, A., Sethi, A. K., et al. (2013). Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. J. Hosp. Infect. 85, 155-158. doi: 10.1016/j.jhin.2013.07.002
69. Hafiz, S., and Oakley, C. L. (1976). Clostridium difficile: isolation and characteristics. J. Med. Microbiol. 9, 129-136. doi: 10.1099/00222615-9-2-129
70. Hagel, S., Epple, H.-J., Feurle, G. E., Kern, W. V., Lynen Jansen, P., Malfertheiner, P., et al. (2015). S2k-Leitlinie Gastrointestinale Infektionen und Morbus Whipple. Z. Gastroenterol. 53, 418-459. doi: 10.1055/s-0034-1399337
71. Hall, I. C., and O'Toole E. (1935). Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child. 2, 390-402. doi: 10.1001/archpedi.1935.01970020105010
72. Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., and Sadowsky, M. J. (2013). High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4, 125-135. doi: 10.4161/gmic.23571
73. Hell, M., Sickau, K., Chmelizek, G., Kern, J. M., Maass, M., Huhulescu, S., et al. (2012). Absence of Clostridium difficile in asymptomatic hospital staff. Am. J. Infect. Control 40, 1023-1024. doi: 10.1016/j.ajic.2012.01.018
74. Henrich, T. J., Krakower, D., Bitton, A., and Yokoe, D. S. (2009). Clinical risk factors for severe Clostridium difficile-associated disease. Emerg. Infect. Dis. 15, 415-422. doi: 10.3201/eid1503.080312
75. Hopkins, M. J., Sharp, R., and Macfarlane, G. T. (2001). Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 48, 198-205. doi: 10.1136/gut.48.2.198
76. Howerton, A., Ramirez, N., and Abel-Santos, E. (2011). Mapping interactions between germinants and Clostridium difficile spores. J. Bacteriol. 193, 274-282. doi: 10.1128/JB.00980-10
77. Huurre, A., Kalliomäki, M., Rautava, S., Rinne, M., Salminen, S., and Isolauri, E. (2008). Mode of delivery-effects on gut microbiota and humoral immunity. Neonatology 93, 236-240. doi: 10.1159/000111102
78. Ishida, Y., Maegawa, T., Kondo, T., Kimura, A., Iwakura, Y., Nakamura, S., et al. (2004). Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J. Immunol. 172, 3018-3025. doi: 10.4049/jimmunol.172.5.3018
79. Jakobsson, H. E., Jernberg, C., Andersson, A. F., Sjölund-Karlsson, M., Jansson, J. K., and Engstrand, L. (2010). Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 5:e9836. doi: 10.1371/journal.pone.0009836
80. Jangi, S., and Lamont, J. T. (2010). Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J. Pediatr. Gastroenterol. Nutr. 51, 2-7. doi: 10.1097/MPG.0b013e3181d29767
81. Jump, R. L. P., Pultz, M. J., and Donskey, C. J. (2007). Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob. Agents Chemother. 51, 2883-2887. doi: 10.1128/AAC.01443-06
82. Kallen, A. J., Thompson, A., Ristaino, P., Chapman, L., Nicholson, A., Sim, B.-T., et al. (2009). Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect. Control Hosp. Epidemiol. 30, 264-272. doi: 10.1086/595694
83. Kassam, Z., Lee, C. H., Yuan, Y., and Hunt, R. H. (2013). Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 108, 500-508. doi: 10.1038/ajg.2013.59
84. Kato, H., Kita, H., Karasawa, T., Maegawa, T., Koino, Y., Takakuwa, H., et al. (2001). Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J. Med. Microbiol. 50, 720-727. doi: 10.1099/0022-1317-50-8-720
85. Keel, K., Brazier, J. S., Post, K. W., Weese, S., and Songer, J. G. (2007). Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J. Clin. Microbiol. 45, 1963-1964. doi: 10.1128/JCM.00224-07
86. Kelly, C. P. (1996). Immune response to Clostridium difficile infection. Eur. J. Gastroenterol. Hepatol. 8, 1048-1053. doi: 10.1097/00042737-199611000-00004
87. Kelly, C. P., and LaMont, J. T. (1998). Clostridium difficile infection. Annu. Rev. Med. 49, 375-390. doi: 10.1146/annurev.med.49.1.375
88. Khanafer, N., Vanhems, P., Barbut, F., and Luxemburger, C. (2017). Factors associated with Clostridium difficile infection: a nested case-control study in a three year prospective cohort. Anaerobe 44, 117-123. doi: 10.1016/j.anaerobe.2017.03.003
89. Khanna, S., Baddour, L. M., Huskins, W. C., Kammer, P. P., Faubion, W. A., Zinsmeister, A. R., et al. (2013). The epidemiology of Clostridium difficile infection in children: a population-based study. Clin. Infect. Dis. 56, 1401-1406. doi: 10.1093/cid/cit075
90. Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., et al. (2016). A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214, 173-181. doi: 10.1093/infdis/jiv766
91. Kim, J. H., Toy, D., and Muder, R. R. (2011). Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect. Control Hosp. Epidemiol. 32, 656-660. doi: 10.1086/660767
92. Kobayashi, T. (1983). Studies on Clostridium difficile and antimicrobial associated diarrhea or colitis. Jpn. J. Antibiot. 36, 464-476
93. Komatsu, M., Kato, H., Aihara, M., Shimakawa, K., Iwasaki, M., Nagasaka, Y., et al. (2003). High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur. J. Clin. Microbiol. Infect. Dis. 22, 525-529. doi: 10.1007/s10096-003-0992-5
94. Kong, L. Y., Dendukuri, N., Schiller, I., Bourgault, A.-M., Brassard, P., Poirier, L., et al. (2015). Predictors of asymptomatic Clostridium difficile colonization on hospital admission. Am. J. Infect. Control 43, 248-253. doi: 10.1016/j.ajic.2014.11.024
95. Kuijper, E. J., Coignard, B., and Tüll, P. (2006). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6), 2-18. doi: 10.1111/j.1469-0691.2006.01580.x
96. Kyne, L., Warny, M., Qamar, A., and Kelly, C. P. (2000). Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342, 390-397. doi: 10.1056/NEJM200002103420604
97. Kyne, L., Warny, M., Qamar, A., and Kelly, C. P. (2001). Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189-193. doi: 10.1016/S0140-6736(00)03592-3
98. Larson, H. E., Barclay, F. E., Honour, P., and Hill, I. D. (1982). Epidemiology of Clostridium difficile in infants. J. Infect. Dis. 146, 727-733. doi: 10.1093/infdis/146.6.727
99. Lawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., et al. (2012). Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8:e1002995. doi: 10.1371/journal.ppat.1002995
100. Leekha, S., Aronhalt, K. C., Sloan, L. M., Patel, R., and Orenstein, R. (2013). Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors. Am. J. Infect. Control 41, 390-393. doi: 10.1016/j.ajic.2012.09.023
101. Lessa, F. C., Winston, L. G., and McDonald, L. C. (2015). Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 2369-2370. doi: 10.1056/NEJMc1505190
102. Ley, R. E., Peterson, D. A., and Gordon, J. I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837-848. doi: 10.1016/j.cell.2006.02.017
103. Lo Vecchio, A., and Zacur, G. M. (2012). Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr. Opin. Gastroenterol. 28, 1-9. doi: 10.1097/MOG.0b013e32834bc9a9
104. Longtin, Y., Paquet-Bolduc, B., Gilca, R., Garenc, C., Fortin, E., Longtin, J., et al. (2016). Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C. difficile infections: a quasi-experimental controlled study. JAMA Intern. Med. 176, 796-804. doi: 10.1001/jamainternmed.2016.0177
105. Loo, V. G., Bourgault, A.-M., Poirier, L., Lamothe, F., Michaud, S., Turgeon, N., et al. (2011). Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med. 365, 1693-1703. doi: 10.1056/NEJMoa1012413
106. Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., et al. (2005). A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442-2449. doi: 10.1056/NEJMoa051639
107. Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431. doi: 10.1056/NEJMoa0910812
108. Lyerly, D. M., Saum, K. E., MacDonald, D. K., and Wilkins, T. D. (1985). Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47, 349-352
109. Lyras, D., O'Connor, J. R., Howarth, P. M., Sambol, S. P., Carter, G. P., Phumoonna, T., et al. (2009). Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179. doi: 10.1038/nature07822
110. Manges, A. R., Labbe, A., Loo, V. G., Atherton, J. K., Behr, M. A., Masson, L., et al. (2010). Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J. Infect. Dis. 202, 1877-1884. doi: 10.1086/657319
111. Marciniak, C., Chen, D., Stein, A. C., and Semik, P. E. (2006). Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch. Phys. Med. Rehabil. 87, 1086-1090. doi: 10.1016/j.apmr.2006.03.020
112. Mariat, D., Firmesse, O., Levenez, F., Guimarães, V., Sokol, H., Doré, J., et al. (2009). The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 9:123. doi: 10.1186/1471-2180-9-123
113. Matamoros, S., Gras-Leguen, C., Le Vacon, F., Potel, G., and de La Cochetiere, M.-F. (2013). Development of intestinal microbiota in infants and its impact on health. Trends Microbiol. 21, 167-173. doi: 10.1016/j.tim.2012.12.001
114. Maziade, P.-J., Pereira, P., and Goldstein, E. J. C. (2015). A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin. Infect. Dis. 60(Suppl. 2), S144-S147. doi: 10.1093/cid/civ178
115. McCusker, M. E., Harris, A. D., Perencevich, E., and Roghmann, M.-C. (2003). Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis. 9, 730-733. doi: 10.3201/eid0906.020385
116. McDonald, L. C., Owings, M., and Jernigan, D. B. (2006). Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 12, 409-415. doi: 10.3201/eid1205.051064
117. McFarland, L. V., Beneda, H. W., Clarridge, J. E., and Raugi, G. J. (2007a). Implications of the changing face of Clostridium difficile disease for health care practitioners. Am. J. Infect. Control 35, 237-253. doi: 10.1016/j.ajic.2006.06.004
118. McFarland, L. V., Clarridge, J. E., Beneda, H. W., and Raugi, G. J. (2007b). Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin. Infect. Dis. 45, 1141-1151. doi: 10.1086/522187
119. McFarland, L. V., Elmer, G. W., Stamm, W. E., and Mulligan, M. E. (1991). Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect. Immun. 59, 2456-2462
120. McFarland, L. V., Mulligan, M. E., Kwok, R. Y., and Stamm, W. E. (1989). Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320, 204-210. doi: 10.1056/NEJM198901263200402
121. McFarland, L. V., Ozen, M., Dinleyici, E. C., and Goh, S. (2016). Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J. Gastroenterol. 22, 3078-3104. doi: 10.3748/wjg.v22.i11.3078
122. Merrigan, M. M., Sambol, S. P., Johnson, S., and Gerding, D. N. (2003). Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188, 1922-1927. doi: 10.1086/379836
123. Merrigan, M. M., Sambol, S. P., Johnson, S., and Gerding, D. N. (2009). New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int. J. Antimicrob. Agents 33(Suppl. 1), S46-S50. doi: 10.1016/S0924-8579(09)70017-2
124. Meyer, G. K. A., Neetz, A., Brandes, G., Tsikas, D., Butterfield, J. H., Just, I., et al. (2007). Clostridium difficile toxins A and B directly stimulate human mast cells. Infect. Immun. 75, 3868-3876. doi: 10.1128/IAI.00195-07
125. Miller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A., et al. (2010). Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50, 194-201. doi: 10.1086/649213
126. Moore, P., Kyne, L., Martin, A., and Solomon, K. (2013). Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure. J. Med. Microbiol. 62, 1405-1413. doi: 10.1099/jmm.0.056614-0
127. Morris, J. G., Jarvis, W. R., Nunez-Montiel, O. L., Towns, M. L., Thompson, F. S., Dowell, V. R., et al. (1984). Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. Arch. Intern. Med. 144, 967-969. doi: 10.1001/archinte.1984.00350170109020
128. Muegge, B. D., Kuczynski, J., Knights, D., Clemente, J. C., González, A., Fontana, L., et al. (2011). Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 332, 970-974. doi: 10.1126/science.1198719
129. Muto, C. A., Pokrywka, M., Shutt, K., Mendelsohn, A. B., Nouri, K., Posey, K., et al. (2005). A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273-280. doi: 10.1086/502539
130. Naaber, P., Lehto, E., Salminen, S., and Mikelsaar, M. (1996). Inhibition of adhesion of Clostridium difficile to Caco-2 cells. FEMS Immunol. Med. Microbiol. 14, 205-209. doi: 10.1111/j.1574-695X.1996.tb00288.x
131. Nakamura, S., Mikawa, M., Nakashio, S., Takabatake, M., Okado, I., Yamakawa, K., et al. (1981). Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol. Immunol. 25, 345-351. doi: 10.1111/j.1348-0421.1981.tb00036.x
132. Nelson, D. E., Auerbach, S. B., Baltch, A. L., Desjardin, E., Beck-Sague, C., Rheal, C., et al. (1994). Epidemic Clostridium difficile-associated diarrhea: role of second-and third-generation cephalosporins. Infect. Control Hosp. Epidemiol. 15, 88-94. doi: 10.2307/30145537
133. Novack, L., Kogan, S., Gimpelevich, L., Howell, M., Borer, A., Kelly, C. P., et al. (2014). Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. PLoS One 9:e110790. doi: 10.1371/journal.pone.0110790
134. Nylund, C. M., Goudie, A., Garza, J. M., Fairbrother, G., and Cohen, M. B. (2011). Clostridium difficile infection in hospitalized children in the United States. Arch. Pediatr. Adolesc. Med. 165, 451-457. doi: 10.1001/archpediatrics.2010.282
135. Ogra, P. L. (2010). Ageing and its possible impact on mucosal immune responses. Ageing Res. Rev. 9, 101-106. doi: 10.1016/j.arr.2009.07.007
136. Ozaki, E., Kato, H., Kita, H., Karasawa, T., Maegawa, T., Koino, Y., et al. (2004). Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J. Med. Microbiol. 53, 167-172. doi: 10.1099/jmm.0.05376-0
137. Pakpour, S., Bhanvadia, A., Zhu, R., Amarnani, A., Gibbons, S. M., Gurry, T., et al. (2017). Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment. Microbiome 5:148. doi: 10.1186/s40168-017-0368-1
138. Peach, S. L., Borriello, S. P., Gaya, H., Barclay, F. E., and Welch, A. R. (1986). Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J. Clin. Pathol. 39, 1013-1018. doi: 10.1136/jcp.39.9.1013
139. Pépin, J., Valiquette, L., and Cossette, B. (2005). Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173, 1037-1042. doi: 10.1503/cmaj.050978
140. Peterfreund, G. L., Vandivier, L. E., Sinha, R., Marozsan, A. J., Olson, W. C., Zhu, J., et al. (2012). Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One 7:e46966. doi: 10.1371/journal.pone.0046966
141. Pirs, T., Ocepek, M., and Rupnik, M. (2008). Isolation of Clostridium difficile from food animals in Slovenia. J. Med. Microbiol. 57, 790-792. doi: 10.1099/jmm.0.47669-0
142. Pochapin, M. (2000). The effect of probiotics on Clostridium difficile diarrhea. Am. J. Gastroenterol. 95, S11-S13. doi: 10.1016/S0002-9270(99)00809-6
143. Pruitt, R. N., and Lacy, D. B. (2012). Toward a structural understanding of Clostridium difficile toxins A and B. Front. Cell. Infect. Microbiol. 2:28. doi: 10.3389/fcimb.2012.00028
144. Rajilic-Stojanovic, M., Heilig, H. G. H. J., Molenaar, D., Kajander, K., Surakka, A., Smidt, H., et al. (2009). Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ. Microbiol. 11, 1736-1751. doi: 10.1111/j.1462-2920.2009.01900.x
145. Rea, M. C., Clayton, E., O'Connor, P. M., Shanahan, F., Kiely, B., Ross, R. P., et al. (2007). Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J. Med. Microbiol. 56, 940-946. doi: 10.1099/jmm.0.47085-0
146. Rea, M. C., O'Sullivan, O., Shanahan, F., O'Toole, P. W., Stanton, C., Ross, R. P., et al. (2012). Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J. Clin. Microbiol. 50, 867-875. doi: 10.1128/JCM.05176-11
147. Reeves, A. E., Koenigsknecht, M. J., Bergin, I. L., and Young, V. B. (2012). Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect. Immun. 80, 3786-3794. doi: 10.1128/IAI.00647-12
148. Reeves, A. E., Theriot, C. M., Bergin, I. L., Huffnagle, G. B., Schloss, P. D., and Young, V. B. (2011). The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2, 145-158. doi: 10.4161/gmic.2.3.16333
149. Reichardt, C., Chaberny, I. F., Kola, A., Mattner, F., Vonberg, R. P., and Gastmeier, P. (2007). Dramatischer Anstieg von Clostridium-difficile-assoziierter Diarrhoe in Deutschland: Ist der neue Stamm PCR-Ribotyp 027 bereits angekommen? Dtsch. Med. Wochenschr. 132, 223-228. doi: 10.1055/s-2007-959314
150. Richardson, S. A., Alcock, P. A., and Gray, J. (1983). Clostridium difficile and its toxin in healthy neonates. Br. Med. J. (Clin. Res. Ed) 287:878. doi: 10.1136/bmj.287.6396.878
151. Riggs, M. M., Sethi, A. K., Zabarsky, T. F., Eckstein, E. C., Jump, R. L. P., and Donskey, C. J. (2007). Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis. 45, 992-998. doi: 10.1086/521854
152. Ringel, Y., and Maharshak, N. (2013). Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G529-G541. doi: 10.1152/ajpgi.00207.2012
153. Robinson, C. J., and Young, V. B. (2010). Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 1, 279-284. doi: 10.4161/gmic.1.4.12614
154. Rodriguez-Palacios, A., Reid-Smith, R. J., Staempfli, H. R., Daignault, D., Janecko, N., Avery, B. P., et al. (2009). Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg. Infect. Dis. 15, 802-805. doi: 10.3201/eid1505.081084
155. Rodriguez-Palacios, A., Staempfli, H. R., Duffield, T., and Weese, J. S. (2007). Clostridium difficile in retail ground meat, Canada. Emerg. Infect. Dis. 13, 485-487. doi: 10.3201/eid1303.060988
156. Rolfe, R. D., and Song, W. (1995). Immunoglobulin and non-immunoglobulin components of human milk inhibit Clostridium difficile toxin A-receptor binding. J. Med. Microbiol. 42, 10-19. doi: 10.1099/00222615-42-1-10
157. Rousseau, C., Poilane, I., Pontual, L., de Maherault, A.-C., Le Monnier, A., and Collignon, A. (2012). Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin. Infect. Dis. 55, 1209-1215. doi: 10.1093/cid/cis637
158. Rupnik, M., Wilcox, M. H., and Gerding, D. N. (2009). Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7, 526-536. doi: 10.1038/nrmicro2164
159. Sambol, S. P., Merrigan, M. M., Tang, J. K., Johnson, S., and Gerding, D. N. (2002). Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186, 1781-1789. doi: 10.1086/345676
160. Samore, M. H., DeGirolami, P. C., Tlucko, A., Lichtenberg, D. A., Melvin, Z. A., and Karchmer, A. W. (1994). Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin. Infect. Dis. 18, 181-187. doi: 10.1093/clinids/18.2.181
161. Sarker, M. R., and Paredes-Sabja, D. (2012). Molecular basis of early stages of Clostridium difficile infection: germination and colonization. Future Microbiol. 7, 933-943. doi: 10.2217/fmb.12.64
162. Schirmer, J., and Aktories, K. (2004). Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim. Biophys. Acta 1673, 66-74. doi: 10.1016/j.bbagen.2004.03.014
163. Schultsz, C., van den Berg, F. M., Kate, F. W., ten Tytgat, G. N., and Dankert, J. (1999). The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117, 1089-1097. doi: 10.1016/S0016-5085(99)70393-8
164. Schwartz, K. L., Darwish, I., Richardson, S. E., Mulvey, M. R., and Thampi, N. (2014). Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. BMC Pediatr. 14:28. doi: 10.1186/1471-2431-14-28
165. Sekirov, I., Russell, S. L., Antunes, L. C. M., and Finlay, B. B. (2010). Gut microbiota in health and disease. Physiol. Rev. 90, 859-904. doi: 10.1152/physrev.00045.2009
166. Shen, A. (2012). Clostridium difficile toxins: mediators of inflammation. J. Innate Immun. 4, 149-158. doi: 10.1159/000332946
167. Shen, N. T., Maw, A., Tmanova, L. L., Pino, A., Ancy, K., Crawford, C. V., et al. (2017). Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 152, 1889.e9-1900.e9. doi: 10.1053/j.gastro.2017.02.003
168. Shim, J. K., Johnson, S., Samore, M. H., Bliss, D. Z., and Gerding, D. N. (1998). Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351, 633-636. doi: 10.1016/S0140-6736(97)08062-8
169. Simor, A. E., Bradley, S. F., Strausbaugh, L. J., Crossley, K., and Nicolle, L. E. (2002). Clostridium difficile in long-term-care facilities for the elderly. Infect. Control Hosp. Epidemiol. 23, 696-703. doi: 10.1086/501997
170. Songer, J. G., Jones, R., Anderson, M. A., Barbara, A. J., Post, K. W., and Trinh, H. T. (2007). Prevention of porcine Clostridium difficile-associated disease by competitive exclusion with nontoxigenic organisms. Vet. Microbiol. 124, 358-361. doi: 10.1016/j.vetmic.2007.04.019
171. Sorg, J. A., and Sonenshein, A. L. (2008). Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190, 2505-2512. doi: 10.1128/JB.01765-07
172. Spigaglia, P. (2016). Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther. Adv. Infect. Dis. 3, 23-42. doi: 10.1177/2049936115622891
173. Stark, P. L., and Lee, A. (1982). Clostridia isolated from the feces of infants during the first year of life. J. Pediatr. 100, 362-365. doi: 10.1016/S0022-3476(82)80430-7
174. Steele, J., Mukherjee, J., Parry, N., and Tzipori, S. (2013). Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J. Infect. Dis. 207, 323-330. doi: 10.1093/infdis/jis669
175. Stevens, V., Dumyati, G., Fine, L. S., Fisher, S. G., and van Wijngaarden, E. (2011). Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin. Infect. Dis. 53, 42-48. doi: 10.1093/cid/cir301
176. Sullivan, A., Edlund, C., and Nord, C. E. (2001). Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1, 101-114. doi: 10.1016/S1473-3099(01)00066-4
177. Tattevin, P., Buffet-Bataillon, S., Donnio, P.-Y., Revest, M., and Michelet, C. (2013). Clostridium difficile infections: do we know the real dimensions of the problem? Int. J. Antimicrob. Agents 42(Suppl.), S36-S40. doi: 10.1016/j.ijantimicag.2013.04.009
178. Tedesco, F. J., Barton, R. W., and Alpers, D. H. (1974). Clindamycin-associated colitis. A prospective study. Ann. Intern. Med. 81, 429-433. doi: 10.7326/0003-4819-81-4-429
179. Terveer, E. M., Crobach, M. J. T., Sanders, I. M. J. G., Vos, M. C., Verduin, C. M., and Kuijper, E. J. (2017). Detection of Clostridium difficile in feces of asymptomatic patients admitted to the hospital. J. Clin. Microbiol. 55, 403-411. doi: 10.1128/JCM.01858-16
180. Theriot, C. M., Koenigsknecht, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, B., et al. (2014). Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5:3114. doi: 10.1038/ncomms4114
181. Thompson, C. M., Gilligan, P. H., Fisher, M. C., and Long, S. S. (1983). Clostridium difficile cytotoxin in a pediatric population. Am. J. Dis. Child. 137, 271-274. doi: 10.1001/archpedi.1983.02140290057015
182. Trzasko, A., Leeds, J. A., Praestgaard, J., Lamarche, M. J., and McKenney, D. (2012). Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob. Agents Chemother. 56, 4459-4462. doi: 10.1128/AAC.06355-11
183. van Dorp, S. M., Smajlovic, E., Knetsch, C. W., Notermans, D. W., de Greeff, S. C., and Kuijper, E. J. (2017). Clinical and microbiological characteristics of Clostridium difficile infection among hospitalized children in the Netherlands. Clin. Infect. Dis. 64, 192-198. doi: 10.1093/cid/ciw699
184. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., and de Vos, W. M., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415. doi: 10.1056/NEJMoa1205037
185. Vardakas, K. Z., Polyzos, K. A., Patouni, K., Rafailidis, P. I., Samonis, G., and Falagas, M. E. (2012). Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int. J. Antimicrob. Agents 40, 1-8. doi: 10.1016/j.ijantimicag.2012.01.004
186. Vernaya, M., McAdam, J., and Hampton, M. D. (2017). Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: a systematic review. JBI Database System. Rev. Implement. Rep. 15, 140-164. doi: 10.11124/JBISRIR-2016-003234
187. Vincent, C., Miller, M. A., Edens, T. J., Mehrotra, S., Dewar, K., and Manges, A. R. (2016). Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 4:12. doi: 10.1186/s40168-016-0156-3
188. Vincent, C., Stephens, D. A., Loo, V. G., Edens, T. J., Behr, M. A., Dewar, K., et al. (2013). Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 1:18. doi: 10.1186/2049-2618-1-18
189. Viscidi, R., Willey, S., and Bartlett, J. G. (1981). Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 81, 5-9
190. Voth, D. E., and Ballard, J. D. (2005). Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18, 247-263. doi: 10.1128/CMR.18.2.247-263.2005
191. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., et al. (2005). Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084. doi: 10.1016/S0140-6736(05)67420-X
192. Weese, J. S. (2010). Clostridium difficile in food-innocent bystander or serious threat? Clin. Microbiol. Infect. 16, 3-10. doi: 10.1111/j.1469-0691.2009.03108.x
193. Welkon, C. J., Long, S. S., Thompson, C. M., and Gilligan, P. H. (1985). Clostridium difficile in patients with cystic fibrosis. Am. J. Dis. Child. 139, 805-808. doi: 10.1001/archpedi.1985.02140100067032
194. Werner, H., and Kuntsche, J. (2000). Infektionen im Alter-was ist anders? Z. Gerontol. Geriatr. 33, 350-356. doi: 10.1007/s003910070031
195. Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., et al. (2017). Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N. Engl. J. Med. 376, 305-317. doi: 10.1056/NEJMoa1602615
196. Wilson, K. H. (1983). Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J. Clin. Microbiol. 18, 1017-1019
197. Wilson, K. H., and Perini, F. (1988). Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect. Immun. 56, 2610-2614
198. Wilson, K. H., Silva, J., and Fekety, F. R. (1981). Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect. Immun. 34, 626-628
199. Winston, J. A., Thanissery, R., Montgomery, S. A., and Theriot, C. M. (2016). Cefoperazone-treated mouse model of clinically-relevant Clostridium difficile strain R20291. J. Vis. Exp. 118:e54850. doi: 10.3791/54850
200. Wongwanich, S., Pongpech, P., Dhiraputra, C., Huttayananont, S., and Sawanpanyalert, P. (2001). Characteristics of Clostridium difficile strains isolated from asymptomatic individuals and from diarrheal patients. Clin. Microbiol. Infect. 7, 438-441. doi: 10.1046/j.1198-743x.2001.00308.x
201. Woodmansey, E. J. (2007). Intestinal bacteria and ageing. J. Appl. Microbiol. 102, 1178-1186. doi: 10.1111/j.1365-2672.2007.03400.x
202. Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., et al. (2011). Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105-108. doi: 10.1126/science.1208344
203. Wullt, M., Hagslätt, M.-L. J., and Odenholt, I. (2003). Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 35, 365-367. doi: 10.1080/00365540310010985
204. Yaeger, M. J., Kinyon, J. M., and Glenn Songer, J. (2007). A prospective, case control study evaluating the association between Clostridium difficile toxins in the colon of neonatal swine and gross and microscopic lesions. J. Vet. Diagn. Invest. 19, 52-59. doi: 10.1177/104063870701900108
205. Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., et al. (2012). Human gut microbiome viewed across age and geography. Nature 486, 222-227. doi: 10.1038/nature11053
206. Zacharioudakis, I. M., Zervou, F. N., Pliakos, E. E., Ziakas, P. D., and Mylonakis, E. (2015). Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am. J. Gastroenterol. 110, 381-390; quiz 391. doi: 10.1038/ajg.2015.22
207. Zilberberg, M. D., Shorr, A. F., and Kollef, M. H. (2008). Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr. Infect. Dis. J. 27, 1111-1113. doi: 10.1097/INF.0b013e31817eef13
208. Zupancic, M. L., Cantarel, B. L., Liu, Z., Drabek, E. F., Ryan, K. A., Cirimotich, S., et al. (2012). Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS One 7:e43052. doi: 10.1371/journal.pone.0043052